MacrogenicsFRA:M55 +4.04%47 Market Cap is €260.1 Mil as of Jul. 09, 2026. GuruFocus rates FRA:M55 with a GF Score™ of 47/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,421 Biotechnology companies, Macrogenics ranks better than 63.19% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Macrogenics's share price for the quarter that ended in Mar. 2026 was €2.384. Macrogenics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 63.6 Mil. Therefore, Macrogenics's market cap for the quarter that ended in Mar. 2026 was €151.5 Mil.
Macrogenics's quarterly market cap
declined
from Sep. 2025 (€93.2 Mil) to Dec. 2025 (€83.3 Mil) but then
increased
from Dec. 2025 (€83.3 Mil) to Mar. 2026 (€151.5 Mil).
Macrogenics's annual market cap
declined
from Dec. 2023 (€555.5 Mil) to Dec. 2024 (€191.6 Mil) and
declined
from Dec. 2024 (€191.6 Mil) to Dec. 2025 (€83.3 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Macrogenics's Enterprise Value for Today is €156.7 Mil.
Macrogenics (FRA:M55) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Macrogenics Market Cap Related Terms
Macrogenics Market Cap Historical Data
* Premium members only.
The historical data trend for Macrogenics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:M55 vs IMRX, TRDA, SLNCF: Market Cap Comparison
For the Biotechnology subindustry, Macrogenics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Macrogenics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Macrogenics's Market Cap distribution charts can be found below:
* The bar in red indicates where Macrogenics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Macrogenics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Macrogenics (FRA:M55) has a Market Cap of €260.1 Mil as of Jul. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Macrogenics and its competitors. According to the industry distribution chart, Macrogenics ranks #523 out of 1421 companies in the Biotechnology industry, placing it in the top 36.8%.
Is Macrogenics' Market Cap too high?
Macrogenics' current Market Cap is €260.1 Mil. Based on the distribution chart, Macrogenics ranks #523 out of 1421 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Market Cap compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #523 out of 1421 companies for Market Cap. This puts Macrogenics in the upper half of its industry. The industry median Market Cap is 119.86. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.86, based on 1,421 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Macrogenics and its competitors. For the Biotechnology industry, the median Market Cap is 119.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Market Cap is €260.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current Market Cap is €260.1 Mil. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Market Cap is €260.1 Mil as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Macrogenics (FRA:M55) Overvalued in 2026?
Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued.
The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59.
GuruFocus considers Macrogenics to be Modestly Overvalued.
Key valuation signals for FRA:M55:
Market Cap: €260.1 Mil
GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score
Get the complete analysis for FRA:M55
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M55 has been successfully added to your 
